Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Ondine Biomedical, Inc. ( (GB:OBI) ).
Ondine Biomedical Inc. has announced the publication of its 2025 Annual General Meeting (AGM) notice and proxy form on its website. The AGM will be held virtually on June 26, 2025, and shareholders are encouraged to vote by proxy. Key agenda items include the re-election of directors and the re-appointment of auditors. The outcomes of the AGM will be shared on the company’s website post-meeting.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products in development, leveraging its proprietary technology. Its nasal photodisinfection system, Steriwave®, is approved in several countries and is undergoing clinical trials in the US.
Average Trading Volume: 142,819
Technical Sentiment Signal: Strong Sell
Current Market Cap: £37.67M
See more data about OBI stock on TipRanks’ Stock Analysis page.